IL-MI-JACK
1.6.2022 17:12:06 CEST | Business Wire | Press release
Mi-Jack Products, the industry leader in Rubber Tired Gantry (RTG) Cranes, container handling machinery, and technology for port and intermodal facilities, has announced a successful acquisition of Yardeye GmbH, a Germany-based automation, collision avoidance, and work zone protection provider for the port and rail container industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005458/en/
Yardeye’s RFID and GNSS-based equipment, personnel Real Time Locating System (RTLS), and Collision Avoidance System (CAS) fit seamlessly into Mi-Jack's Mi-Star® technology platform, which provides everything from differential GPS automated steering and GPS inventory management to virtualized operations view and centralized fleet management.
Combining both companies’ skilled and experienced technology groups into one will facilitate continued innovation and excellence for automation, collision avoidance, and work zone protection within ports and intermodal terminals.
Aaron Newton, VP of Sales for Mi-Jack, said, “By bringing these two similar but unique technology platforms together, the port and intermodal industries will now have an end-to-end automation solution with superior redundancy, led by a company [Mi-Jack] that’s been rooted in the container handling business for over 65 years.”
According to Simon Fiera, VP of Technology at Mi-Jack, “We see Yardeye as a key component of integrating into an agnostic crane manufacturing base for the purposes of automation and work zone protection. We look forward to the innovations and efficiencies that will come from combining the skillsets and experiences of both the European and North American technology teams.”
With this expanded footprint, Mi-Jack brings its world class support and service to Yardeye customers in North America and will provide Mi-Star technology solutions to ports and terminals across Europe. Mi-Jack provides 24/7/365 service and parts support and has a vast network of highly trained technicians and solutions experts that service customers both in-person and virtually.
Stephan Trauth, Managing Director of Yardeye, said, “We are very proud to join the Mi-Jack group. The know-how of both companies will generate more advanced capabilities and synergies. Together, we will provide an automation portfolio that sets new standards in the rail container industry. The network from Mi-Jack in the North American market and especially their competence will add more value and innovative ideas for our customers. We look forward to this new chapter!”
Christian Augustin, Founder of Yardeye and managing director of indurad said, “The team has been growing Yardeye since 2017 from a concept to a company with a global impact serving the intermodal and container handling industry. We are very proud with what we have achieved, and we believe that together with Mi-Jack, Yardeye will continue its success story, for our customers as well as our employees. indurad and I will continue to focus our activities on radar technology for bulk material handling.”
About Mi-Jack
Mi-Jack is recognized worldwide as an industry leader and innovator in rubber-tired gantry (RTG) cranes and other products and solutions globally. Mi-Jack's Mi-Star suite of automation technology includes AccuSteer , AccuStack , AccuView , VehicleView , and AccuFleet . Mi-Star is installed on thousands of pieces of equipment throughout the world.
Corporate headquarters are in Hazel Crest, Illinois at an ISO 9001:2017 certified facility that produces Translift™ and Travelift® RTG’s now in use on six continents. The company maintains four regional operations headquarters and five sales offices. Mi-Jack is part of the Lanco Group of Companies . For more information, go to www.mi-jack.com .
About Yardeye
Yardeye GmbH (www.yardeye.com ) operates internationally with a focus on port automation and work zone protection in container terminals. By Yardeye’s unique GNSS, RFID, and collisional avoidance technology, terminals are able to identify and track cranes, vehicles, and personnel for efficient intermodal yard operations and work zone protection.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005458/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom